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Abstract
Background—Hypertrophic cardiomyopathy (HCM) is often caused by sarcomere gene 
mutations, resulting in left ventricular hypertrophy (LVH), myocardial fibrosis, and increased risk 
of sudden cardiac death and heart failure. Studies in mouse models of sarcomeric HCM 
demonstrated that early treatment with an angiotensin receptor blocker (ARB) reduced 
development of LVH and fibrosis. In contrast, prior human studies using ARBs for HCM have 
targeted heterogeneous adult cohorts with well-established disease. The VANISH trial is testing 
the safety and feasibility of disease-modifying therapy with an ARB in genotyped HCM patients 
with early disease.
Methods—A randomized, placebo-controlled, double-blind clinical trial is being conducted in 
sarcomere mutation carriers, 8 to 45 years old, with HCM and no/minimal symptoms, or those 
with early phenotypic manifestations but no LVH. Participants are randomly assigned to receive 
valsartan 80 to 320 mg daily (depending on age and weight) or placebo. The primary endpoint is a 
composite of 9 z-scores in domains representing myocardial injury/hemodynamic stress, cardiac 
morphology, and function. Total z-scores reflecting change from baseline to final visits will be 
compared between treatment groups. Secondary endpoints will assess the impact of treatment on 
mutation carriers without LVH, and analyze the influence of age, sex, and genotype.
Conclusions—The VANISH trial is testing a new strategy of disease modification for treating 
sarcomere mutation carriers with early HCM, and those at risk for its development. In addition, 
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further insight into disease mechanisms, response to therapy, and phenotypic evolution will be 
gained.
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder that affects up to 1 
in 500 people.1 The disease has traditionally been defined as left ventricular hypertrophy 
(LVH) that occurs in the absence of identifiable triggers, such as pressure overload or 
infiltrative disease. At a histopathologic level, HCM is characterized by myocyte 
hypertrophy, disarray, and fibrosis. Most patients with HCM have normal longevity; 
however, effort intolerance, symptomatic heart failure, and atrial fibrillation may cause 
substantial morbidity, despite medical or invasive therapy.2–4 HCM can also have serious 
clinical consequences, including end-stage heart failure and sudden cardiac death. Notably, 
HCM is an important cause of sudden cardiac death in competitive athletes, adolescents, and 
young adults in the United States.5
Hypertrophic cardiomyopathy is often caused by mutations in genes encoding sarcomere 
proteins6 and is the most common monogenic heart disease. Pathogenic sarcomere 
mutations have been identified in up to 60% of patients with a family history of HCM.7 
However, both the penetrance and phenotypic expression of sarcomere mutations are 
variable and highly age-dependent. Left ventricular wall thickness (LVWT), often normal 
during early childhood, typically increases in adolescence and young adulthood. Genetic 
testing allows at-risk sarcomere mutation carriers (G+) to be identified before diagnostic 
clinical features appear and thus before potentially irreversible changes to the myocardium 
are in place. Genetic testing also distinguishes sarcomeric HCM from other conditions that 
may similarly result in the relatively crude phenotype of “unexplained” LVH, but have 
different underlying causes and biology. Collectively, these factors provide remarkable 
opportunities to implement disease-modifying treatments in genetically susceptible 
individuals at a time when treatment may be most successful. Effective treatment would 
diminish disease progression, thereby reducing the morbidity and mortality associated with 
HCM.
Study rationale
Currently, HCM is treated only with therapy to palliate symptoms or with implantable 
cardioverter-defibrillators to prevent sudden cardiac death for patients considered to have 
increased risk. No treatments have been proven to alter the natural history of disease or to be 
beneficial for either sarcomere mutation carriers with normal LV wall thickness (denoted 
preclinical HCM) or for asymptomatic patients with HCM. With improved understanding of 
how sarcomere mutations cause HCM, more rational and mechanistic treatments can be 
developed, targeting early, disease-initiating pathways. The goal of these therapies would be 
to attenuate disease progression and, ultimately, disease emergence.8
Studies in mouse models of sarcomeric HCM have indicated the importance of transforming 
growth factor beta (TGF-β) activation in early disease pathogenesis.9 Although the 
mechanisms are not fully understood, numerous studies indicate that angiotensin II binding 
to the angiotensin type 1 receptor activates canonical and non-canonical TGF-β signaling 
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pathways, stimulating pathways of collagen synthesis and inhibiting collagen degradation.10 
Angiotensin receptor blockers (ARBs) can inhibit TGF-β activation.11
Two complementary strategies to reduce TGF-β activation decreased disease progression in 
a mouse model of sarcomeric HCM12 (Figure 1). Treatment with either TGF-β neutralizing 
antibodies or with the angiotensin II type 1 receptor blocker, losartan, were shown to 
attenuate the development of myocyte hypertrophy and fibrosis in treated animals compared 
with those receiving placebo. Notably, treatment was effective only when started at a young 
age, before LVH was established. In contrast, prior clinical studies using ARBs in patients 
with HCM targeted heterogeneous patient populations with well-established disease and 
have not shown consistent benefit.13–18
In a randomized clinical trial, the safety and efficacy of valsartan, an angiotensin II, type I-
selective angiotensin receptor blocker, is being evaluated in modifying the course of HCM. 
The target population is an at-risk population with early sarcomeric disease identified 
through clinical evaluation and genetic testing. The trial is testing the hypothesis that 
valsartan will have beneficial effects on reducing adverse changes in cardiac structure, 
function, and serum biomarker concentrations, indicating attenuated progression of HCM. 
Here, we summarize the study protocol of this trial. The authors are solely responsible for 
the design and conduct of this study, all study analyses, the drafting and editing of the 
manuscript, and its final contents.
Trial design
The VANISH study is a phase II multicenter, randomized, placebo-controlled, double-blind 
clinical trial. Two cohorts of sarcomere mutation carriers will be enrolled: one with early 
disease (primary analysis cohort) and one at a preclinical stage with increased risk for 
developing HCM (exploratory cohort). Each cohort will have both a treatment and a placebo 
group.
The primary analysis cohort consists of sarcomere mutation carriers 8 to 45 years old with at 
least borderline LVH who are asymptomatic or mildly symptomatic (New York Heart 
Association (NYHA) class I–II). Patients in this cohort are anticipated to have early disease, 
given their relatively young age and minimal symptom burden. The primary analysis will be 
performed on this cohort (target enrollment of 150 subjects) because disease pathways are 
more likely to be already activated and these patients may be more responsive to therapy.
The exploratory cohort consists of mutation carriers 10 to 25 years old who have normal LV 
wall thickness (no diagnosis with HCM) but some evidence of phenotypic impact, such as 
impaired relaxation (reduced tissue Doppler E′ velocity) or electrocardiographic 
abnormalities (Q waves or ST changes). Evidence of phenotypic impact was included as an 
eligibility criterion for this cohort because disease progression during the study period is not 
expected to be substantial in mutation carriers without any discernible abnormalities at 
enrollment. No enrollment target is specified for the exploratory cohort.
Patients in each cohort are randomly assigned to receive either valsartan or placebo for 2 
years (Figure 2). Study procedures are identical for the 2 cohorts. The trial is being 
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conducted in the HCMNet collaborative network (Table I) and is registered at 
ClinicalTrials.gov (NCT01912534). An independent Data Safety Monitoring Board will 
oversee the conduct of the trial. This trial is funded by the National Institutes of Health 
(NIH, 1P50HL112349). Valsartan and matching placebo tablets have been donated by 
Novartis Pharmaceuticals Corporation. Novartis had no part in developing this protocol and 
will not be involved in data analysis or publication decisions.
Patient selection and eligibility criteria
All patients must have a pathogenic or likely pathogenic HCM sarcomere mutation and 
provide informed consent. Variant pathogenicity is determined using standard criteria 
accounting for segregation, conservation, literature review, review of publicly available 
databases,7,19,20 and very low frequency in appropriate ethnically-matched control 
populations (Exome Aggregation Consortium [ExAC], Cambridge, MA [URL: http://
exac.broadinstitute.org]).21 A panel with expertise in genotyping, led by the principal 
investigator, reviews each questionable variant and approves or denies eligibility by 
consensus. Inclusion and exclusion criteria are listed in Table II.
Eligibility criteria were selected to attempt to target therapy to individuals that are most 
likely to respond (in the treatment group) or to demonstrate phenotypic progression (in the 
placebo group). The age limits for each cohort also considered the delayed penetrance of 
sarcomere mutations. Mutation carriers typically develop clinical manifestations during or 
after adolescence, although disease expression is variable and may be incomplete. Patients 
older than 45 years are excluded from the primary cohort out of concern that prolonged 
exposure to disease may have resulted in irreversible changes that will not respond to 
disease-modifying therapy. Children under 10 years of age are excluded from the 
exploratory cohort given the low likelihood that phenotypic progression will occur in very 
young children during the trial. Similarly, patients older than 25 years are excluded from the 
exploratory cohort out of concern that sarcomere mutation carriers who have not expressed a 
more pronounced phenotype by this age may have substantially delayed penetrance or be 
non-penetrant mutation carriers and thus unlikely to progress during the trial.
Treatment and active run-in period
High doses of ARBs are generally believed necessary to inhibit TGF-β, although the 
threshold for efficacy is unknown. Therefore, the maximum FDA approved dose of valsartan 
was chosen as the target dose (adults, 320 mg daily; children <17 years old weighing ≥35 
kg, 160 mg daily; children <17 years old weighing <35 kg, 80 mg daily). To ensure that 
patients can be maintained on the target dose, eligible patients first enter a 2- to 6-week 
active run-in period during which the dose is titrated up to the target dose. Only those who 
tolerate the target dose are randomly assigned and maintained on blinded therapy for 2 
years.
Stratification and random assignment
After baseline data collection and successfully completing active run-in, eligible patients are 
randomly assigned in a 1:1 ratio to receive to valsartan or placebo (Figure 3). Subjects 
determined to be ineligible and those who do not tolerate active run-in will be followed in a 
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registry with information gathered from clinical evaluation. Because group assignment, age, 
pubertal status, and baseline NYHA class are anticipated to influence outcomes and 
phenotypic progression, the randomization scheme is stratified by each of these factors. This 
stratification effectively creates 2 parallel trials: one comprised the primary analysis cohort 
of patients with early disease and the other comprised the exploratory cohort of patients at 
elevated risk for disease expression. Patients with borderline LVH (LV wall thickness 12–14 
mm or z-score of 4–6) may be in the early stages of phenotypic evolution and may be 
expected to either have a more dynamic course or be more responsive to treatment than 
those with much more established and severe LVH. Therefore, the primary analysis cohort 
will also be stratified by LV wall thickness (<14 vs ≥14 mm or z-score of 6).
The randomization scheme is stratified with a block size of 4 and with cells defined by 
NYHA class, pubertal status, and entry LV wall thickness (stratification factors shown in the 
Supplemental Figure). The Data Coordinating Center (DCC) generates the randomization 
lists for each stratum using SAS programming and enters these lists into the data 
management system (eCOS). When a participant’s eligibility and stratification for 
randomization is determined, eCOS will assign the participant the next treatment from the 
list for that stratum. After assignment, a participant will remain on the same Treatment 
Allocation Code for the duration of the study. Only the DCC has access to the randomization 
lists; participants and investigators are blinded to the study treatment.
Follow-up visits and procedures
Family history is assessed at baseline and updated at subsequent visits (Table III). Three-
generation pedigrees are constructed to capture family structure and history of HCM and 
related complications. Physical examination, collection of blood samples for safety 
assessment and for biomarker analysis, 12-lead electrocardiograms, and trans-thoracic 
echocardiography are obtained at baseline, year 1, and year 2. In addition, these visits will 
assess quality of life (using validated Pediatric Quality of Life Inventory forms22 appropriate 
for the patient’s age) and physical activity using the abbreviated version of the Physical 
Activity and Physical Fitness survey of the National Health and Nutrition Examination 
survey (NHANES Physical Activity and Cardiovascular Fitness Data Tutorial. http://
www.cdc.gov/nchs/tutorials/PhysicalActivity/SurveyOrientation/DataOverview/ [Accessed 
July 18, 2016]). Physical activity is also being assessed with FitBit activity monitors 
(accelerometer/pedometer) worn by participants for the duration of the trial.
Cardiopulmonary exercise testing and cardiac magnetic resonance imaging (CMR; if not 
contraindicated) are performed at baseline and year 2. CMR will obtain information 
adjunctive to echocardiography on cardiac structure and function. In addition, to assess 
myocardial tissue characteristics, replacement fibrosis will be estimated by quantifying late 
gadolinium enhancement, and T1 mapping will estimate effective extracellular volume. All 
imaging and exercise testing studies are obtained with standardized protocols, and 
personnel, blinded to treatment assignment but not to the purpose of the trial, will analyze 
echocardiographic, CMR, exercise testing, electrocardiographic, and biomarker data at core 
laboratories (Supplemental Table).
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Blood for biomarker analysis is processed within 60 minutes of phlebotomy and stored at 
−80°C. Validated, commercial immunoassays will examine multiple potential biomarkers of 
disease progression by monitoring myocardial injury (including high-sensitivity cardiac 
troponin I and T), hemodynamic stress (including natriuretic peptides, and soluble ST2), and 
collagen metabolism.23 Assays for all samples will be run at the end of the trial. Additional 
assays may be included as guided by state-of-the-art knowledge available at the time of data 
analysis. Remaining samples will be banked for future study. In addition, blood for safety 
laboratory assessments will be drawn at the end of the run-in period and yearly to detect 
renal dysfunction and hyperkalemia. Doses will be reduced on confirmation that the serum 
potassium concentration is greater than 5 mmol/L, or that the estimated glomerular filtration 
rate (eGFR) decreased by 25% or more, as determined by the modified Schwartz formula for 
children24 or the CKD-EPI equation for adults,25 or for eGFR <75/1.73 m2. Laboratory 
studies will be repeated within 1 week, and treatment will be stopped if values do not 
improve despite dose reduction.
Trial timeline and preliminary baseline characteristics of randomized subjects
Enrollment is estimated to require 32 months and began in April 2014. As of September 
2016, 139 patients have been enrolled, including 114 in the primary analysis cohort (76% of 
target enrollment) (Table IV). The baseline characteristics of the randomized subjects to date 
demonstrate recruitment of intended population. Participants will receive study medication 
for 24 months and trial completion is anticipated in 2019. All participating sites have 
received institutional review or ethics board approval and all participants have provided 
informed consent.
Statistical analysis plan
Developing the statistical analysis plan for the VANISH trial faced the following challenges: 
(1) the effect of valsartan in modifying disease is unknown; (2) objective clinical outcomes 
(such as death or major adverse clinical events) are unlikely to occur during the trial because 
participants are young and relatively healthy; (3) factors that drive disease progression and 
outcomes in HCM are unknown; (4) surrogate outcomes that are potentially responsive to 
therapy or associated with a strong and consistent treatment effects have not yet been 
identified for early HCM; and (5) with the modest sample size in the VANISH trial, the 
power to detect a small but clinically important difference in any single outcome variable 
may be insufficient.
Therefore, rather than trying to detect a large effect of valsartan on a single outcome 
measure, our analysis focuses on identifying a series of composite outcome measures that 
are relevant to the pathophysiology of HCM, reflecting 3 domains of cardiac structure, 
function, and myocardial injury or stress (Table V). We postulate that consistent moderate 
effects across the component measures in these domains will indicate an important treatment 
response, and will be more sensitive than monitoring any single component in isolation. 
Individual variables captured in these domains will measure LV wall thickness, LV cavity 
size, diastolic function, longitudinal systolic function, and serum biomarkers of myocardial 
stress and injury. These variables (increased LV wall thickness, decreased cavity size, 
diastolic and longitudinal systolic dysfunction, and increased biomarkers) have been shown 
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to reflect early phenotypic expression of sarcomere mutations.26–28 As such, they are 
anticipated to be clinically relevant surrogate outcomes to monitor treatment response and 
disease progression. Values for each of the component outcomes from each domain will be 
provided by the appropriate core laboratories and then summed to create a single composite 
outcome z-score.29 We hypothesize that valsartan treatment will improve the primary 
composite z-score, indicating an important treatment response. We believe that this approach 
of assessing non-redundant variables that monitor relevant aspects of cardiac structure and 
function provides the highest likelihood of detecting any apparent signal of treatment effect 
and/or disease progression. This strategy has been used successfully in other phase II heart 
failure trials.30,31
Analysis will be performed as intention-to-treat after all patients have completed 2 years of 
treatment. The primary efficacy analyses will be based on an average change in the 
composite z-score across the 3 domains listed above. For each patient and each component, 
the change between baseline and 24 months will be calculated. Using the anticipated 
distribution of data, relative change (percent change from baseline) will be used to evaluate 
serum biomarker concentrations, and absolute change will be used for all other components. 
Higher composite z-scores reflect relatively greater improvement in phenotype in one or 
more components of the composite outcome.
Sample size considerations—Power calculations for the composite z-score were based 
on the work of Sun et al,29 who considered a composite z-score of 6 measures commonly 
used in heart failure trials. Simulations were used to calculate the power for a composite z-
score of the 3 domains described above, with the same correlation of 0.12 between 
component measures and assuming that the z-score for each domain would show a 
standardized beneficial effect of valsartan of between 0.22 and 0.25 z-score standard 
deviations. Given these assumptions, the target enrollment for VANISH is 150 patients in the 
primary cohort (75 per treatment arm), which provides an estimated 76% to 88% power to 
detect standardized effect sizes of 0.22 to 0.25 z-score SDs.
Primary safety analyses—To determine whether valsartan is safe, well-tolerated, and 
does not reduce the quality of life of young, asymptomatic patients, we will compare the 
incidence of adverse drug reactions, frequency of treatment discontinuation, and responses 
to the Pediatric Quality of Life Inventory forms22 between the valsartan and placebo groups.
Secondary analyses—A variety of complementary and biologically relevant metrics will 
be analyzed to characterize more broadly the impact of valsartan on disease pathology. 
Improvement in, stability, or attenuation of progression in metrics of interest will be 
assessed, including the 9 components of the composite outcome, other measures of LV and 
left atrial size, new measures of LV systolic and diastolic function, measures of metabolic 
exercise testing, and new serum biomarkers.
Several features are anticipated to affect treatment response and the natural history of the 
disease. Therefore, pre-specified subgroup analyses will consider phenotypic status (primary 
analysis versus exploratory cohorts), sex, underlying genotype (MYBPC3, MYH7, TNNI3, 
and TNNT2), pubertal status, growth by height velocity during the trial, and baseline LV 
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wall thickness. Due to the diverse geography of the participating sites, the influence of 
participating site and ethnicity will also be explored in secondary analyses.
The effect of valsartan on the exploratory cohort in isolation will be analyzed as described 
for the primary analysis cohort. In addition, the effect of valsartan on development of LVH 
and clinically overt HCM will be analyzed. A Clinical Events Committee comprised of adult 
and pediatric cardiologists will adjudicate clinical outcomes (hospitalization or unscheduled 
clinical visits, development of atrial or ventricular arrhythmias, need for procedures, etc) for 
evaluation in secondary analyses. Quality of life and physical activity metrics will also be 
analyzed.
When the trial was first designed, the primary analysis cohort had more restrictive eligibility 
requirements, including an upper age of 30 years and a maximum LV wall thickness of ≤20 
mm (z-score ≤14). Owing to difficulties identifying a sufficiently large cohort of individuals 
meeting entrance criteria for trial enrollment (which began in April 2014), the eligibility 
criteria were modified and are as shown in Table II. Thus, the impact of treatment using the 
original eligibility criteria will be assessed with sensitivity analyses. Furthermore, up to 5 
members of the same family are permitted to participate. Although family membership will 
be accounted for in the statistical analysis, the impact of relatedness will be assessed with 
sensitivity analyses by including only the first family member enrolled.
In addition to continuous outcome variables, each participant will be scored as a “success” 
or “failure” based on improvement in any of the 9 component z-scores at 24 months. The 
proportion of successes and failures will be compared between treatment groups in 
secondary analyses using Fisher’s exact test and adjusted for confounding with logistic 
regression.
Discussion
Determining the genetic basis of inherited heart disease provides the remarkable opportunity 
to define the specific cause of disease, to identify at-risk individuals before clinical 
diagnosis, and to develop new therapies intended to diminish or prevent clinical expression. 
Based on the knowledge and mechanistic insight gained from basic science discovery, 
clinical trials can now be developed to explore whether pharmacologic therapy may 
counteract the phenotypic expression of an inherited gene mutation. The VANISH trial will 
investigate this new paradigm for genetic cardiomyopathy by testing the safety and efficacy 
of using valsartan as disease-modifying therapy for patients anticipated to be in the early 
stages of sarcomeric HCM.
Several trials have investigated the use of ARBs in regressing disease in adults with 
established HCM.13–18 Results have been inconsistent and no strong signals of benefit have 
been detected. Notably, these studies have had several key limitations. All but the study by 
Axelsson et al18 included fewer than 30 patients. The patient cohorts were heterogeneous 
and may not have targeted the most responsive patient population. For example, prior studies 
targeted older adults and did not incorporate genotyping into eligibility criteria. In contrast, 
all preclinical work supporting the use of ARB therapy used young animals with sarcomere 
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mutations in the pre-hypertrophic stage of disease. Therefore, the patients enrolled in prior 
studies included many whose disease may have been irreversibly entrenched and not 
responsive to disease-modifying treatment.
The VANISH trial was designed to address the limitations and the unanswered questions 
associated with earlier trials of ARB therapy in HCM. Particular attention was paid to 
capture patients anticipated to be most responsive to disease-modifying therapy. Younger 
patients with less advanced disease are targeted for because they may be at a more plastic 
and modifiable period in disease evolution. Furthermore, patients are required to have 
genetically-confirmed sarcomeric HCM to focus study on a cohort that most closely 
replicates the fundamental basis for the trial.
Limitations of the trial
Few clinical trials have tested disease-modifying therapies in genetic heart disease and 
important challenges are present. The underlying pathophysiology of HCM typically evolves 
over years to decades, requiring large numbers of patients to be followed over long periods; 
an approach beyond the scope of this Phase II trial of patients with a relatively rare disease. 
The young, healthy patients in this trial are anticipated to have low event rates, making it 
difficult to detect treatment response. As such, this trial will rely on a composite of 9 
surrogate endpoints believed to reflect the pathophysiology of HCM and important aspects 
of cardiac structure and function, but whose relationship to clinical disease has not yet been 
firmly established. Choosing the target dose of valsartan for this trial was difficult because 
this strategy has not been previously tested, and because it is not possible to accurately 
translate doses used in mouse models to those that will be required to affect change in 
humans.
Conclusions
By helping to pioneer disease-modifying therapy, the VANISH trial has the potential to 
advance the care of patients and families with inherited cardiomyopathies. Experience 
gained with patient selection and with the surrogate outcomes used in this Phase II trial will 
yield valuable information to inform the development of future clinical trials. Analogous 
data from the placebo groups will further understanding of factors that influence disease 
progression and clinical outcomes in patients with sarcomeric HCM. This knowledge will 
help target therapy to responsive individuals at highest risk who may receive the greatest 
benefit from new strategies for disease modification and prevention. As such, VANISH can 
serve as a paradigm for learning how to harness genetic insights to better understand 
pathogenesis and advance clinical practice. By fostering discovery of new ways to disrupt 
disease progression, a precision approach of gene-based diagnosis and management can be 
brought closer to reality.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Proposed model of how sarcomere mutations may lead to hypertrophic cardiomyopathy and 
the potential impact of angiotensin receptor blockade. Studies using mouse models of 
hypertrophic cardiomyopathy (HCM) have suggested that sarcomere mutations increase 
force generation and calcium sensitivity, and activate profibrotic pathways early in disease 
pathogenesis, before cardiac hypertrophy develops. These abnormalities activate numerous 
cellular pathways, including transforming growth factor-beta (TGF-β) signaling pathways, 
culminating in the development of myocardial fibrosis and hypertrophy. In mouse models of 
HCM, inhibiting TGF-β activation, using either neutralizing antibody or losartan, attenuated 
the development of left ventricular hypertrophy and fibrosis if given early in the 
prehypertrophic phase of disease (modified from Teekakirikul P, et al. JCI; 2010 (12)).
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Figure 2. 
VANISH trial schema. This schematic illustrates the overall structure of the trial from 
patient selection to completion of 2 years of blinded therapy, followed by primary and 
secondary analyses.
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Figure 3. 
Summary of the flow from enrollment to randomization in the VANISH Trial. Participants 
will undergo baseline studies and await rapid echocardiographic core laboratory evaluation 
to confirm eligibility and to determine whether they will be stratified to the primary or 
exploratory cohort (based on measurement of maximal left ventricular wall thickness, LV 
thickness to dimension ratio, and E′ velocity). Eligible participants will then enter into 
active run-in and undergo up titration of valsartan to target dose over the course of 2 to 6 
weeks. Those who tolerate active run-in will undergo stratified randomization and begin 24-
months of blinded treatment with study medication. Ineligible subjects will be followed in a 
registry.
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Table I
Participating sites for the VANISH trial
Trial site Principal investigator Location
Brigham and Women’s Hospital Carolyn Ho, MD (Trial Principal Investigator) Boston, MA
University of Michigan Sharlene Day, MD;
Mark Russell, MD
Ann Arbor, MI
Cleveland Clinic Foundation Harry Lever, MD;
Kenneth Zahka, MD
Cleveland, OH
Boston Children’s Hospital Steven Colan, MD;
Renee Margossian, MD
Boston, MA
 Yale University (virtual site) Kevin Hall, MD New Haven, CT
Vanderbilt University Jason Becker, MD Nashville, TN
Cincinnati Children’s Hospital Medical Center John Lynn Jeffries, MD Cincinnati, OH
University of Chicago Amit Patel, MD Chicago, IL
 Northwestern University (virtual site) Lubna Choudhury, MD
Johns Hopkins University Anne Murphy, MD Baltimore, MD
Washington University School of Medicine Charles Canter, MD;
Richard Bach, MD
St. Louis, MO
University of Colorado, Denver Matthew Taylor, MD;
Luisa Mestroni, MD
Denver, CO
Stanford University Matthew Wheeler, MD Palo Alto, CA
Toronto Hospital for Sick Children Lee Benson, MD Toronto, ON Canada
Hospital of the University of Pennsylvania Anjali Owens, MD Philadelphia, PA
Children’s Hospital of Philadelphia Joseph Rossano, MD;
Kim Lin, MD
Philadelphia, PA
Lurie Children’s Hospital of Chicago Elfriede Pahl, MD Chicago, IL
Penn State Health, Hershey Medical Center Eric Popjes, MD Hershey, PA
Massachusetts General Hospital Michael Fifer, MD Boston, MA
INCOR (Instituto do Coração) Alexandre Pereira, MD Sao Paolo, Brazil
Rigshospitalet Henning Bundgaard, MD;
Anna Axelsson Raja, MD
Copenhagen, Denmark
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Table II
Eligibility criteria for the VANISH trial
Inclusion Criteria Exclusion Criteria
Primary analysis cohort
1 Age 8 to 45 years
2 LV wall thickness ≥ 12 mm and ≤25 mm or z-score ≥ 3 
and ≤18 as determined by rapid assessment by the 
echocardiographic core laboratory
3 NYHA functional class I or II
4 No resting or provoked LV obstruction (peak gradient 
≤30 mm Hg)
Exploratory analysis cohort
1 Age 10 to 25 years
2 LV wall thickness< 12 mm and z score< 3 as 
determined by rapid assessment by the 
echocardiographic core laboratory
3 Evidence of phenotypic expression: early diastolic 
relaxation velocity (E′) z-score ≤ −1.5 or 
electrocardiographic abnormalities other than non-
specific ST-T wave changes (e.g., Q waves, T wave 
inversion, repolarization changes) or LV wall thickness 
z-score 1.5 to 2.9 combined with LV thickness to 
dimension ratio ≥ 0.19 as determined by rapid 
assessment by the echocardiographic core laboratory
1 Contraindication to angiotensin receptor blocker 
(ARB) administration
2 Medical conditions that may confound interpretation of 
biomarkers of collagen synthesis (fibrosis, 
inflammatory states, cancer, trauma or surgery within 6 
months of enrollment)
3 Concomitant use of spironolactone, lithium, aliskiren, 
ARB, or angiotensin converting enzyme (ACE)-
inhibitors.
4 Pregnant or breastfeeding women or women of 
childbearing potential with no effective contraceptive 
method
5 Uncontrolled systemic arterial hypertension (persistent 
systolic blood pressure> 160 mmHg and/or diastolic 
blood pressure> 90 mmHg in adults or equivalent in 
children [e.g., systolic blood pressure > 99th or 
diastolic blood pressure> 95th percentile for sex, age, 
and height centile based on the American Academy of 
Pediatrics normal values])
6 Prior septal myectomy, alcohol septal ablation, or 
treatment for symptomatic heart failure
7 Known or suspected coronary artery disease or 
evidence of prior myocardial infarction based on 
symptoms or cardiac imaging
8 More than mild valvular heart disease, clinically 
relevant congenital heart disease, or left ventricular 
ejection fraction (LVEF) <55%
9 Secondary prevention implantable cardioverter-
defibrillator (ICD) or history of appropriate ICD 
therapy
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Table IV
Demographic characteristics of VANISH patients as of September 27, 2016
Variable Overall, N = 139 Primary cohort, N = 114 Exploratory cohort, N = 25
Age at baseline, mean (SD), years 20.3 (8.9) 21.1 (9.5) 16.6 (4.5)
Sex, n (%)
 Female   60 (43)   51 (45)     9 (36)
 Male   79 (57)   63 (55)   16 (64)
Race, n (%)
 White 134 (96) 109 (96)     25 (100)
 Black   0 (0)
 Other   5 (4)   5 (4)
Maximal LV Wall Thickness Z-Score, mean (SD)   6.0 (4.1)   6.8 (4.2)   2.0 (0.7)
E″ lateral Z-Score, mean (SD) −1.6 (1.4) −1.8 (1.3) −0.4 (1.0)
LVEF (%), mean (SD), years 65 (7) 67 (7) 63 (4)
Peak VO2, mean (SD), mL/kg/min 33.8 (9.8)   32.8 (10.0) 37.3 (8.3)
NYHA class, n (%)
 I 134 (96) 109 (96)    25 (100)
 II   5 (4)   5 (4)
Gene, n (%)
 MYBPC3   67 (49)   55 (50)   12 (48)
 MYH7   47 (35)   37 (33)   10 (40)
 TNNT2   9 (7)   9 (8) 0
 TNNI3   5 (4)   3 (3) 0
LV, Left ventricle; EF, ejection fraction; VO2, volume of oxygen consumption; NYHA, New York Heart Association; MYBPC3, myosin binding 
protein C; MYH7, myosin heavy chain; TNNT2, cardiac troponin T; TNNI3, cardiac troponin I.
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Table V
Outcome domains and components for the primary composite endpoint
Domain Component outcomes
Serum biomarkers of myocardial injury and stress High-sensitivity cardiac troponin NTproBNP
Cardiac morphology CMR LV mass*
CMR LA volume*
CMR end-diastolic LV volume*
CMR end-systolic LV volume*
Echocardiographic maximum LV wall thickness z-score
Cardiac function Echocardiographic E′ z-score
Echocardiographic S′ z-score
NTproBNP, Amino terminal propeptide of B-type natriuretic peptide; CMR, cardiac magnetic resonance imaging; LA, left atrium; LV, left 
ventricle.
*CMR metrics will be indexed to body surface area; echocardiographic z-scores to substitute if CMR imaging unavailable.
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